Advertisement
Cancer-associated incidental pulmonary embolism should be treated with low molecular weight heparins

Review Supports LMWH for Cancer-Linked Incidental PE

0
VTE recurrence risk similar under LMWHs, vitamin K antagonists; risk of major hemorrhage up under VKA
For patients with liver cirrhosis

Low-Dose Rifaximin Cuts Endotoxin Level in Cirrhosis

0
Similar reduction in serum endotoxin level for low-dose, high-dose rifaximin
For patients with rheumatoid arthritis and inflammatory bowel disease with prior nonmelanoma skin cancer (NMSC)

Some RA Treatments Up Second Nonmelanoma Skin Cancer Risk

0
Increased risk with methotrexate, and for anti-TNF drugs in conjunction with methotrexate
For patients with acute myocardial infarction

Part D Enrollment Doesn’t Improve Outcomes After AMI

0
Half of AMI patients enrolled in Part D by hospital discharge; outcomes no better than non-enrollees
For black patients with asthma treated with inhaled corticosteroids

LABAs No Better Than Tiotropium in Black Adults With Asthma

0
Outcomes similar for patients treated with inhaled corticosteroids plus tiotropium versus LABAs
A considerable proportion of federal marketplace plans lack at least one in-network specialist

Nearly 15 Percent of Plans Lack In-Network Specialists

0
Most commonly excluded specialists are in endocrinology, rheumatology, and psychiatry
In a case report published in the October issue of Clinical Diabetes

Case of Lactic Acidosis With Metformin, Normal Renal Function

0
Patient presented to ER with coughing and shortness of breath, normal renal function
Women are more often treated with low-dose dabigatran

Women More Often Treated With Low-Dose Dabigatran

0
Despite trend toward lower stroke risk with high dose
Discontinuing statins before non-cardiac surgery is unnecessary and may increase the risk of death following the operation

ASA: Patients Undergoing Surgery Should Stay on Statins

0
Discontinuing med may boost mortality risk during recovery from non-cardiac operations
Imlygic (talimogene laherparepvec) has been approved by the U.S. Food and Drug Administration to treat melanoma lesions of the skin and lymph nodes.

FDA Approves Imlygic for Melanoma

0
Injectable drug designed to rupture and kill cancer cells